Business Standard

R&D expenditure will rise in the coming quarters: Biocon Biologics MD

In a Q&A, Dr Arun Chandavarkar spoke on how its interchangeable insulin biosimilar has driven the business

Biocon Biologics MD Dr Arun Chandavarkar
Premium

Biocon Biologics MD Dr Arun Chandavarkar

Deepsekhar Choudhury Bengaluru
Biocon saw its net profit rising 11 per cent to Rs 187 crore in the third quarter (September to December) even as revenue grew 18 per cent to Rs 2,223 crore. The bright spark for the business was its biosimilars segment which saw a 28 per cent rise in income to Rs 981 crore.

Biocon Biologics managing director Dr Arun Chandavarkar spoke to Business Standard’s Deepsekhar Choudhury on how its interchangeable insulin biosimilar has driven the business, R&D spends in the future and more. Edited excerpts:

What was the revenue impact of interchangeable Semglee on the biologics business in Q3?

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 21 2022 | 7:08 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com